MX2022011879A - Derivados de trapidilo marcados isotopicamente. - Google Patents

Derivados de trapidilo marcados isotopicamente.

Info

Publication number
MX2022011879A
MX2022011879A MX2022011879A MX2022011879A MX2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A MX 2022011879 A MX2022011879 A MX 2022011879A
Authority
MX
Mexico
Prior art keywords
isotopically
labelled
trapidil derivatives
parkinson
disease
Prior art date
Application number
MX2022011879A
Other languages
English (en)
Inventor
Hiroko Masamune
Warren S Wade
Aarash Bordbar
Original Assignee
Sinopia Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinopia Biosciences Inc filed Critical Sinopia Biosciences Inc
Publication of MX2022011879A publication Critical patent/MX2022011879A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan derivados de trapidilo marcados isotópicamente útiles para el tratamiento de la enfermedad de Parkinson y los trastornos del movimiento asociados con la enfermedad de Parkinson. Los derivados de trapidilo marcados isotópicamente incluyen derivados de trapidilo deuterados. Adicionalmente, se proporcionan terapias combinadas de derivados de trapidilo marcados isotópicamente y agentes terapéuticos adicionales para el tratamiento de la enfermedad de Parkinson y los trastornos del movimiento asociados con la enfermedad de Parkinson.
MX2022011879A 2020-03-26 2021-03-25 Derivados de trapidilo marcados isotopicamente. MX2022011879A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000347P 2020-03-26 2020-03-26
US202063063846P 2020-08-10 2020-08-10
PCT/US2021/024226 WO2021195425A1 (en) 2020-03-26 2021-03-25 Isotopically-labelled trapidil derivatives

Publications (1)

Publication Number Publication Date
MX2022011879A true MX2022011879A (es) 2023-01-11

Family

ID=77892379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011879A MX2022011879A (es) 2020-03-26 2021-03-25 Derivados de trapidilo marcados isotopicamente.

Country Status (10)

Country Link
US (1) US12508267B2 (es)
EP (1) EP4125853A4 (es)
JP (2) JP7730336B2 (es)
KR (1) KR20230013023A (es)
CN (3) CN121550230A (es)
AU (1) AU2021244241A1 (es)
CA (1) CA3177066A1 (es)
IL (1) IL296788A (es)
MX (1) MX2022011879A (es)
WO (1) WO2021195425A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054674A1 (en) 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
CN121550230A (zh) 2020-03-26 2026-02-24 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
ES2670927T3 (es) 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
AU2008245458B2 (en) * 2007-04-30 2013-01-10 Abbvie Inc. Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
US8071562B2 (en) 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
US9084820B2 (en) 2008-04-18 2015-07-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Magnetic microstructures for magnetic resonance imaging
EP3564395B1 (en) 2010-12-30 2025-06-25 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
US11285142B2 (en) 2015-09-29 2022-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for identifying and treating dystonia disorders
WO2017117240A1 (en) 2015-12-29 2017-07-06 JONES AND MALTERER TECHNOLOGY INNOVATIONS INCORPORATED, d/b/a JAMTek Multi-point synchronizable and scalable lighting control systems
CA3054674A1 (en) * 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
JP7083397B2 (ja) * 2018-02-02 2022-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体
CA3163242A1 (en) 2019-12-02 2021-06-10 Aarash BORDBAR Treating cognitive disorders using trapidil
CN121550230A (zh) * 2020-03-26 2026-02-24 希诺皮亚生物科学公司 同位素标记的曲匹地尔衍生物
US20230242538A1 (en) 2020-06-24 2023-08-03 Yale University PanK Modulators and Methods Using Same

Also Published As

Publication number Publication date
EP4125853A1 (en) 2023-02-08
TW202547838A (zh) 2025-12-16
WO2021195425A1 (en) 2021-09-30
CN116496279A (zh) 2023-07-28
JP7730336B2 (ja) 2025-08-27
US12508267B2 (en) 2025-12-30
CN116496279B (zh) 2025-12-12
EP4125853A4 (en) 2024-07-03
CA3177066A1 (en) 2021-09-30
CN115916180A (zh) 2023-04-04
TW202202502A (zh) 2022-01-16
IL296788A (en) 2022-11-01
JP2023519289A (ja) 2023-05-10
KR20230013023A (ko) 2023-01-26
JP2025183224A (ja) 2025-12-16
CN121550230A (zh) 2026-02-24
US20230102580A1 (en) 2023-03-30
AU2021244241A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2024006123A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
CY1121408T1 (el) Προληψη και θεραπεια συνουκλεϊνοπαθειας και αμυλοειδοπαθειας
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
LU93321I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
CY1121683T1 (el) Προληψη και θεραπευτικη αγωγη συνουκλεϊνοπαθητικης και αμυλοειδογονου νοσου
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
MX388912B (es) Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
IL282562A (en) Composition and use for the treatment of parkinson's disease and related disorders
MX2022011879A (es) Derivados de trapidilo marcados isotopicamente.
GB0416508D0 (en) Therapeutic agents
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MY135829A (en) Analeptic and drug combinations
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2023003032A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer.
GB0410238D0 (en) Therapeutic agents
MX2024007043A (es) Purinas y métodos de uso.
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
TWI799923B (zh) 硫代咪唑烷酮藥物在治療covid-19疾病中的用途
MX2021005994A (es) Combinacion de gaboxadol y litio para el tratamiento de trastornos psiquiatricos.